Corrected first edition · India / CDSCO

CDSCO Medical Device Biological Safety Submission Playbook

By Arvind RathoreISO 10993 Biocompatibility Consultant · Founder, MedDev Advisory

For teams preparing biological-safety evidence for a non-IVD device dossier in India: map ISO 10993 evidence into the Device Master File.

Read the 16-Page Preview Request Purchase

Real current-edition preview
Controlled source register
Historical v1.0.1 preserved
Exact versioned package hashes

Version 1.1.0 is the corrected current edition. It incorporates the final G.S.R. 743(E) and 744(E) amendment stack. Historical version 1.0.1 remains preserved in the correction history and is not supplied as the current edition.

First Edition · v1.1.0 Source status 21 August 2026 · targeted amendment check 1 September 2026 MDA-HBK-CDSCO-BIO-01

Cover of the CDSCO Medical Device Biological Safety Submission Playbook by Arvind Rathore

184first-edition A4 pages

15decision-led chapters

15original figures

7annotated appendices

59controlled source records

Actual pages, not mock-ups

Inspect the current route, dossier and evidence method

These are direct renders from version 1.1.0. The searchable 16-page preview lets you assess the method and professional boundaries before requesting a written offer.

Contents page for the CDSCO Medical Device Biological Safety Submission Playbook — **Complete contents:** Inspect all five parts, 15 chapters and seven annotated appendices.

Preview page showing an India medical-device regulatory route map — **Route before dossier:** Registration, domestic manufacture, import, applicant and authority roles remain separate.

Preview page showing biological-safety evidence mapped into the India dossier architecture — **Dossier architecture:** Device state, risk management, Essential Principles and biological evidence are cross-referenced without duplication.

Open the 16-Page Preview

What the playbook helps you do

Connect the applied device, evidence and India dossier

Move from route and device identity to a bounded biological-safety narrative that a reviewer can reconstruct without mistaking a global report for India-specific applicability.

Qualify the route

Separate registration, domestic manufacturing, loan-licence, import and investigational contexts before choosing dossier architecture.

Lock the submitted device

Reconcile models, claims, contact, materials, sites, processes, sterilisation, packaging and supplied state to the application.

Control source status

Keep the Rules, final amendments, guidance, FAQs, portal practice, standards and professional inference in their proper lanes.

Map the dossier

Connect Fourth Schedule locations, risk management, Essential Principles and biological evidence without duplicating unsupported claims.

Test evidence applicability

Ask whether each report represents the models, materials, process, site, sterilisation state, use and claim actually submitted.

Answer and maintain

Write bounded narratives, control deficiency responses and reopen the position when device, evidence or source status changes.

Complete contents

A route-to-maintenance workflow for India

Open each part to inspect every chapter in the complete first edition.

PART IQualify the India submissionChapters 1–3

One India Market, Several Regulatory Routes
Lock the Device Identity, Intended Use, Classification, Grouping, and Applicant
Control Legal Sources, Status, Standards, and Claims

PART IIBuild the India evidence mapChapters 4–6

Read the Fourth Schedule as an Evidence Architecture
Connect Device Description, Materials, Contact, Manufacturing, and Sterilisation
Map Biological Evidence into Risk Management and the Essential Principles

PART IIIAssemble the route-specific dossierChapters 7–9

Domestic Class A and Class B: Proportionate Evidence, Registration, and Licensing
Domestic Class C and Class D: Technical Scrutiny and Inspection Readiness
Import Licensing: Foreign Manufacturer, Indian Authorised Agent, and India Dossier

PART IVDefend the biological-safety positionChapters 10–12

Test-Article Representation and Applicability to the Submitted Device
Testing, Prior Evidence, and the Rationale for No New Testing
Integrate Chemistry, Toxicology, Clinical, and Post-Market Evidence Without Duplication

PART VSubmit, answer, and maintainChapters 13–15

Write the Biological-Safety Narrative and Audit-Ready Cross-Reference System
Anticipate and Answer Deficiencies Without Overclaiming
Control Post-Approval Change, Vigilance, and Dossier Maintenance in India

Practical working records

Seven annotated appendices make the reasoning visible

Reference structures show the fields and decision boundaries to transfer into the manufacturer’s controlled QMS records or approved templates.

Route and authority decision

Record the product, intended use, class, grouping, applicant, transaction, authority, legal anchors, assumptions and escalation points.

Fourth Schedule crosswalk

Connect biological-safety evidence to Device Master File locations, risk management and Essential Principles evidence.

Submitted device-state map

Reconcile applied configurations, contact components, materials, manufacturing and sterilisation state.

Evidence applicability and gaps

Bound what each report can support, identify mismatches and assign the next competent owner.

Essential Principles cross-reference

Trace the relevant claim to the current approved evidence rather than a generic statement of conformity.

Deficiency and commitment control

Separate the question, evidence, response, remaining limit, commitment, owner and closure record.

Source-status monitoring

Track source identity, status, checked date, operational role, limitations and events that trigger reassessment.

Final readiness checklist

Challenge whether route, identity, evidence, narrative, owners and unresolved work are visible before submission.

Publication controls

Know exactly what this first edition provides

Publisher control: This founder-authored edition is internally source-checked and supported by a controlled source register, correction history and exact master hashes. No regulator approval or external endorsement is implied. It is professional education—not legal or regulatory advice, a device-specific biological evaluation, a submission or a substitute for current official sources, lawfully obtained standards and qualified judgment.

What it provides

An original route-to-dossier reasoning method.
Four fictional case dossiers with unresolved work kept visible.
Named source categories, status distinctions and monitoring triggers.
Practical reviewer questions, worked exhibits and competence boundaries.

What it does not provide

A CDSCO, Central or State Licensing Authority requirement.
A current consolidation of every MDR amendment or portal instruction.
A device classification, grouping, licence, permission or filing decision.
A qualified toxicological conclusion or guarantee of authority acceptance.

Buyer-specific licensed package

Know what the written offer will identify

Every buyer-specific licensed package is generated for the named buyer and exact accepted tier. The written offer will identify the exact licensed files, version, price, update option, terms and controlled-delivery method before payment.

Searchable tagged PDF

The complete 184-page current reading edition identified by product ID, version and SHA-256 hash.

Editable DOCX by licence

Not included in the Individual tier. It can be included only where the accepted Organisation or Consultant Practice licence expressly allows it.

Controlled source register

Fifty-nine dated source records separating legal anchors, final instruments, guidance, administrative material, standards and limitations.

README and release notes

Edition identity, intended use, boundaries, file orientation, correction treatment and update terms.

CHECKSUMS inside the tier package

SHA-256 checksums identify the customer files inside the sealed package for integrity and document-control verification.

Separate buyer licence and delivery record

The licence certificate and controlled delivery record are issued separately after the applicable offer, identity and payment gates. The internal package manifest is not included in the customer ZIP.

Clear commercial boundary: Online checkout, payment, customer download, and automatic delivery are not currently enabled. Submit a purchase request to receive the exact written offer before you decide whether to pay. Historical version 1.0.1 is preserved in the correction record and is not supplied as the current edition.

Transparent licence pricing

Choose the licence that matches how the playbook will be used

INR applies in India; USD is for eligible international requests and is confirmed in the written offer. Applicable tax is extra. Update Assurance covers eligible updates for 12 months and never renews automatically.

Individual

₹14,900 / $179

Current edition for your own professional work.

₹19,900 / $239 with 12-month updates

Organisation

₹44,900 / $549

Licensed internal use for the named organisation.

₹59,900 / $749 with 12-month updates

Consultant practice

₹74,900 / $899

Professional-use scope for the named consulting practice.

₹99,900 / $1,199 with 12-month updates

Request This Playbook Offer Compare the professional book library

Current official sources: G.S.R. 743(E) and G.S.R. 744(E). The amendments generally commenced on Gazette publication. Only compliance with the new Rule 44 clause (p) is expressly delayed for six months from the notification.

Buyer fit

Built for the team assembling or challenging the India dossier

This playbook is likely a good fit if you…

Lead RA/QA, biological-safety or technical-dossier work for non-IVD devices in India.
Need to reconcile a global ISO 10993 evidence base with applied models, sites and claims.
Coordinate a foreign manufacturer and Indian authorised agent or a domestic manufacturer’s cross-functional team.
Want stronger Fourth Schedule cross-references, evidence-applicability decisions and reviewer-facing narratives.

It is not the right resource if you expect…

A universal CDSCO checklist or one route for every device class.
Reproduced MDR, BIS or ISO text in place of lawfully obtained current sources.
A device-specific classification, grouping, testing, toxicology or biological-safety conclusion.
Regulator endorsement or a guarantee of licence approval.

Fictional cases, real decision pressure

Four dossiers carry the method from route to maintenance

The examples are teaching devices—not client matters, regulator precedents, successful applications or recommendations for a real product.

Class A support

Shows why a reduced registration route is not an evidence vacuum and why self-certification still needs a controlled basis.

Sterile Class B fluid-path set

Exposes the distance between material plaques and the finished, processed, sterilised and packaged device.

Imported catheter family

Tests model, site and evidence reconciliation between the foreign manufacturer and Indian authorised agent.

Bioresorbable implant

Keeps degradation, local-tissue, clinical and investigational uncertainties visible instead of collapsing them into “biocompatible”.

About the author

Arvind Rathore

Arvind Rathore is the founder of MedDev Advisory and works with medical-device teams on biological-evaluation, regulatory and evidence decisions involving device state, chemistry, toxicology, sterilisation, documentation and market-specific submissions.

Before establishing the practice, he was a Marie Skłodowska-Curie Early Stage Researcher at INSERM U1026 Biotis within the ImplantSens network. His work covered implantable electrochemical biosensors, cytotoxicity, oxidative stress, sterilization effects and biomaterial–cell interactions, with research placements in France, Germany and Sweden.

He holds an MTech in Biological Sciences and Bioengineering from IIT Kanpur and has peer-reviewed publications in Bioelectrochemistry, Advanced Sensor Research and Biochimie. His research experience informs the playbook; it does not replace device-specific assessment or specialist review.

Full professional profile Credentials and trust controls

Questions before purchase

Playbook FAQ

Is this CDSCO guidance or an approved submission template?

No. It is a publisher-authored professional education resource. It is not issued, approved, endorsed or sponsored by CDSCO, the Government of India, BIS, ISO or another authority or standards body.

Does it provide a device-specific biological evaluation?

No. It teaches how to connect device state, biological evidence, risk management, Essential Principles and dossier locations. Qualified professionals remain responsible for device-specific conclusions.

Does it cover domestic and import pathways?

Yes. It separates Class A non-sterile and non-measuring registration, domestic Class A/B and C/D licensing contexts, and import-licensing responsibilities without presenting one universal route.

How is the corrected v1.1.0 edition controlled?

It is founder-authored, internally source-checked and supported by a controlled source register, correction history, exact master hashes and buyer-specific package records. No external endorsement is implied.

Can I inspect it before requesting an offer?

Yes. The 16-page public preview contains real selected pages from the current v1.1.0 edition. A written-offer request creates no order or payment obligation.

What is included in the licensed package?

Every buyer-specific licensed package includes the searchable PDF, controlled source register, release notes, README and SHA-256 checksums. The licence certificate and controlled delivery record are issued separately after the accepted offer, buyer details and payment have been verified. The editable DOCX is included only where the accepted Organisation or Consultant Practice licence expressly allows it.

Related expert guide

CDSCO Biocompatibility Documentation Before Testing

Review the India-specific device, route, contact, materials and evidence questions that should be settled before laboratory work begins.

Read: CDSCO Biocompatibility Documentation Before Testing

First-edition purchase enquiries are open

Read the real preview, then request the exact written offer.

Judge the route logic, dossier architecture, correction controls and professional boundaries before deciding whether this playbook belongs in your professional library. Your request creates no order or payment obligation.